Literature DB >> 17467904

Oxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic pain.

Carsten K Nielsen1, Fraser B Ross, Shahrdad Lotfipour, Kamal S Saini, Stephen R Edwards, Maree T Smith.   

Abstract

Previously, we reported that oxycodone is a putative kappa-opioid agonist based on studies where intracerebroventricular (i.c.v.) pre-treatment of rats with the kappa-selective opioid antagonist, nor-binaltorphimine (nor-BNI), abolished i.c.v. oxycodone but not morphine antinociception, whereas pretreatment with i.c.v. naloxonazine (mu-selective antagonist) produced the opposite effects. In the present study, we used behavioural experiments in rat models of mechanical and biochemical nerve injury together with radioligand binding to further examine the pharmacology of oxycodone. Following chronic constriction injury (CCI) of the sciatic nerve in rats, the antinociceptive effects of intrathecal (i.t.) oxycodone, but not i.t. morphine, were abolished by nor-BNI. Marked differences were found in the antinociceptive properties of oxycodone and morphine in streptozotocin (STZ)-diabetic rats. While the antinociceptive efficacy of morphine was abolished at 12 and 24 weeks post-STZ administration, the antinociceptive efficacy of s.c. oxycodone was maintained over 24 weeks, albeit with an approximately 3- to 4-fold decrease in potency. In rat brain membranes irreversibly depleted of mu- and delta-opioid binding sites, oxycodone displaced [(3)H]bremazocine (kappa(2)-selective in depleted membranes) binding with relatively high affinity whereas the selective mu- and delta-opioid ligands, CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH(2)) and DPDPE ([D-Pen(2,5)]-enkephalin), respectively, did not. In depleted brain membranes, the kappa(2b)-ligand, leu-enkephalin, prevented oxycodone's displacement of high-affinity [(3)H]bremazocine binding, suggesting the notion that oxycodone is a kappa(2b)-opioid ligand. Collectively, the present findings provide further support for the notion that oxycodone and morphine produce antinociception through distinctly different opioid receptor populations. Oxycodone appears to act as a kappa(2b)-opioid agonist with a relatively low affinity for mu-opioid receptors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17467904     DOI: 10.1016/j.pain.2007.03.022

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  50 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

2.  Basic opioid pharmacology: an update.

Authors:  Hasan Pathan; John Williams
Journal:  Br J Pain       Date:  2012-02

3.  A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.

Authors:  Anne E Olesen; Richard Upton; David J R Foster; Camilla Staahl; Lona L Christrup; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2010-12       Impact factor: 6.447

Review 4.  Role of active metabolites in the use of opioids.

Authors:  Janet K Coller; Lona L Christrup; Andrew A Somogyi
Journal:  Eur J Clin Pharmacol       Date:  2008-10-29       Impact factor: 2.953

Review 5.  Analysis of Multiple Routes of Analgesic Administration in the Immediate Postoperative Period: a 10-Year Experience.

Authors:  Nalini Vadivelu; Alice M Kai; Feng Dai; Susan Dabu-Bondoc
Journal:  Curr Pain Headache Rep       Date:  2019-03-11

6.  Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone.

Authors:  Joanna C Jacob; Justin L Poklis; Hamid I Akbarali; Graeme Henderson; William L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2017-04-25       Impact factor: 4.030

7.  A population pharmacokinetic and pharmacodynamic study of a peripheral κ-opioid receptor agonist CR665 and oxycodone.

Authors:  Anne E Olesen; Kim Kristensen; Camilla Staahl; Sherron Kell; Gilbert Y Wong; Lars Arendt-Nielsen; Asbjørn M Drewes
Journal:  Clin Pharmacokinet       Date:  2013-02       Impact factor: 6.447

Review 8.  Oxycodone combinations for pain relief.

Authors:  R B Raffa; J V Pergolizzi; D J Segarnick; R J Tallarida
Journal:  Drugs Today (Barc)       Date:  2010-06       Impact factor: 2.245

9.  Effects of oxycodone on brain responses to emotional images.

Authors:  Margaret C Wardle; Daniel A Fitzgerald; Michael Angstadt; Christine A Rabinak; Harriet de Wit; K Luan Phan
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

10.  Differential activation of the μ-opioid receptor by oxycodone and morphine in pain-related brain regions in a bone cancer pain model.

Authors:  Atsushi Nakamura; Minoru Hasegawa; Kazuhisa Minami; Tomoe Kanbara; Takako Tomii; Atsushi Nishiyori; Minoru Narita; Tsutomu Suzuki; Akira Kato
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.